The next phase of GLP-1 growth could extend far beyond what Zepbound already achieved.
Pricing pressure and demand uncertainty are now becoming harder for investors to ignore.
Why today’s headline partnership matters more than it first appears.
What Novo Nordisk’s pill means for long-term investors.
